Here, we created a conditional transgenic mouse model with insertion of a sequence coding for both MYD88 L252P and the Yellow Fluorescent Protein (YFP) into the rosa26-locus. B-cell
Introduction
Accounting for less than five percent of B-cell lymphomas and being an incurable disease, Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a low-grade B-cell lymphoma primarily located in the bone marrow, with an IgM peak and a lymphoplamaspacytic morphological aspect from the small mature lymphocyte to the terminally differentiated plasma cell 1 . WM/LPLs are genetically characterized by activating alterations of MYD88, the most frequent being the MYD88 L265P mutation 2, 3 , that leads to canonical NF-κB activation 4 . Consistently, an in vitro addiction to MYD88 dependent NF-B activation has been reported for the BCWM.1 and MWCL-1 WM cell lines 2 .
But Wang et al. showed that retrovirally enforced expression of MYD88 L265P in primary mouse B cells is rapidly countered by NF-B negative feedbacks which may lead to B-cell death 5 . Knittel et al introduced the Myd88 L252P mutation (the murine orthologous mutation of the human MYD88 L265P mutation) into the Myd88 gene in a B-cell specific manner. These mice occasionally develop spontaneous aggressive B-cell lymphoma when aged, without any IgM peak 6 . Therefore, it is not clear whether continuous activation of MYD88 is responsible on its own of an indolent LPL with an IgM peak or if additional events are required. Here, we present a mouse model in which the MYD88 L252P protein was continuously expressed in the B-cell lineage.
Methods
All material and methods are detailed in supplemental methods.
Results and Discussion
The murine MYD88 L252P protein constitutively induces NF-B activation.
We first created two transgenes with the mutant murine cDNA sequence of Myd88 (Myd88 L252P ) or its wild-type form (Myd88 WT ). Both transgenes were in frame with the Yellow Fluorescent Protein (Yfp) sequence, being separated by an Internal Ribosome Entry Site (IRES) sequence (Myd88 L252P -IRES-Yfp and Myd88 WT -IRES-Yfp inserts) ( Figure 1A) .
The murine A20 cell line was transfected with a pcDNA3.1 expression vector in which was cloned these two inserts. As shown in Figure 1B and 1C, high levels of MYD88 were produced in both cases and high levels of YFP fluorescence were detected. Cotransfection were performed with the vector containing the luciferase reporter gene downstream either a promoter containing native or mutated NF-B binding sites (3X-B-L and 3X-mutB-L vectors respectively). A strong luciferase activity was detected when MYD88 L252P was expressed but not with MYD88 WT ( Figure 1D ). Mutation of the B binding sites completely abolished the luciferase activity of the transfected cells. This indicates that the MYD88 L252P protein was responsible for constitutive NF-B activation. With a fold change of 2, a set of 1515 differentially expressed genes were found in MYD88 L252P spleen tumors when compared to spleen of CD19_Cre mice (Supplemental Table 1 ). This included seventy seven deregulated genes that belong to the plasma cell signature published by Shi et al 9 (Supplemental Table 2 ). Specific unsupervised clustering with these 77 genes revealed that MYD88 L252P tumors exhibited features of plasma cell differentiation such as decreased expression of Cd19 and Msa4 (Cd20) or increased expression of Xbp1 (Figure 2I In the blood, IgM levels continuously increased from month 4 to 12 ( Figure 2J ) and an IgM peak was systematically found in serum of 8 -12 month old MYD88 L252P mice, with constant decrease of the albumin/globulin ratio ( Figure 2K ).
Beside the fact that primary B-cells were ex vivo retrovirally infected before reinjection, the 
